Antigen-Specific Tolerogenic and Immunomodulatory Strategies for the Treatment of Autoimmune Arthritis

Seminars in Arthritis and Rheumatism

Volumn 38, Issue 3, 2008, Pages 195-207

  Satpute, Shailesh R ^a   Durai, Malarvizhi ^b   Moudgil, Kamal D ^c  

^a UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^b DEPARTMENT OF PATHOLOGY   (United States)

^c Division of Rheumatology   (United States)

Author keywords

animal models; autoimmunity; heat shock proteins; immunomodulation; rheumatoid arthritis; tolerance

Indexed keywords

ABATACEPT; ADALIMUMAB; AGGRECAN; ALTERED PEPTIDE LIGAND; ANTIBODY; ANTIGEN; BACTERIAL ANTIGEN; BCG VACCINE; COLLAGEN TYPE 2; CYTOKINE; DNA VACCINE; ETANERCEPT; HEAT SHOCK PROTEIN 10; HEAT SHOCK PROTEIN 60; HEAT SHOCK PROTEIN 65; HEAT SHOCK PROTEIN 70; IMMUNOGLOBULIN HEAVY CHAIN; INFLIXIMAB; INTERLEUKIN 17; RECOMBINANT HEAT SHOCK PROTEIN 65; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; RECOMBINANT INTERLEUKIN 4; RECOMBINANT PROTEIN; SYNTHETIC PEPTIDE; TRYPTOPHAN DERIVATIVE; UNCLASSIFIED DRUG;

ADJUVANT ARTHRITIS; ADOPTIVE IMMUNOTHERAPY; ALLERGIC ENCEPHALOMYELITIS; AMINO ACID SEQUENCE; ANAPHYLAXIS; ANTIGEN SPECIFICITY; ANTIINFLAMMATORY ACTIVITY; ARTICLE; AUTOIMMUNE DISEASE; AUTOIMMUNITY; B LYMPHOCYTE; BIOLOGICAL THERAPY; CD4+ CD25+ T LYMPHOCYTE; CELL BASED GENE THERAPY; CELLULAR IMMUNITY; CLINICAL TRIAL; CYTOKINE PRODUCTION; DNA IMMUNIZATION; HUMAN; IMMUNOLOGICAL TOLERANCE; IMMUNOPATHOGENESIS; IMMUNOTHERAPY; INNATE IMMUNITY; INSULIN DEPENDENT DIABETES MELLITUS; JUVENILE RHEUMATOID ARTHRITIS; MUCOSAL IMMUNITY; MULTIPLE SCLEROSIS; NONHUMAN; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; RHEUMATOID ARTHRITIS; SOMATIC GENE THERAPY; SYSTEMIC LUPUS ERYTHEMATOSUS; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT; UVEITIS; VIRAL GENE THERAPY;

ANIMALS; ARTHRITIS, RHEUMATOID; DISEASE MODELS, ANIMAL; HUMANS; IMMUNE TOLERANCE; IMMUNOLOGIC FACTORS; IMMUNOTHERAPY;

EID: 56349119494     PISSN: 00490172     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.semarthrit.2007.10.002     Document Type: Article

References (178)

1. Lipsky P.E. Rheumatoid arthritis. In: Kasper D.L., Braunwald E., Fauci A.S., et al. (Eds). Harrison's Principles of Internal Medicine. 16th ed. (2005), McGraw-Hill, New York 1968-1977
2. Fontoura P., Garren H., and Steinman L. Antigen-specific therapies in multiple sclerosis: going beyond proteins and peptides. Int Rev Immunol 24 5-6 (2005) 415-446
3. Gaur A., Wiers B., Liu A., Rothbard J., and Fathman C.G. Amelioration of autoimmune encephalomyelitis by myelin basic protein synthetic peptide-induced anergy. Science 258 5087 (1992) 1491-1494
4. Tisch R., Wang B., and Serreze D.V. Induction of glutamic acid decarboxylase 65-specific Th2 cells and suppression of autoimmune diabetes at late stages of disease is epitope dependent. J Immunol 163 3 (1999) 1178-1187
5. Rizzo L.V., and Caspi R.R. Immunotolerance and prevention of ocular autoimmune disease. Curr Eye Res 14 9 (1995) 857-864
6. Wiik A.S. The immune response to citrullinated proteins in patients with rheumatoid arthritis: genetic, clinical, technical, and epidemiological aspects. Clin Rev Allergy Immunol 32 1 (2007) 13-22
7. Kim H.R., Kim E.Y., Cerny J., and Moudgil K.D. Antibody responses to mycobacterial and self heat shock protein 65 in autoimmune arthritis: epitope specificity and implication in pathogenesis. J Immunol 177 10 (2006) 6634-6641
8. Ulmansky R., Cohen C.J., Szafer F., Moallem E., Fridlender Z.G., Kashi Y., et al. Resistance to adjuvant arthritis is due to protective antibodies against heat shock protein surface epitopes and the induction of IL-10 secretion. J Immunol 168 12 (2002) 6463-6469
9. Nepom G.T. Therapy of autoimmune diseases: clinical trials and new biologics. Curr Opin Immunol 14 6 (2002) 812-815
10. Feldmann M., and Steinman L. Design of effective immunotherapy for human autoimmunity. Nature 435 7042 (2005) 612-619
11. Sigal L.H. Basic science for the clinician 26: tolerance-mechanisms and manifestations. J Clin Rheumatol 11 2 (2005) 113-117
12. von Herrath M.G., and Nepom G.T. Lost in translation: barriers to implementing clinical immunotherapeutics for autoimmunity. J Exp Med 202 9 (2005) 1159-1162
13. St Clair E.W., Turka L.A., Saxon A., Matthews J.B., Sayegh M.H., Eisenbarth G.S., et al. New reagents on the horizon for immune tolerance. Annu Rev Med 58 (2007) 329-346
14. Katsiari C.G., and Tsokos G.C. Re-establishment of tolerance: the prospect of developing specific treatment for human lupus. Lupus 13 7 (2004) 485-488
15. Ohashi P.S., Oehen S., Buerki K., Pircher H., Ohashi C.T., Odermatt B., et al. Ablation of "tolerance" and induction of diabetes by virus infection in viral antigen transgenic mice. Cell 65 2 (1991) 305-317
16. Kurts C., Sutherland R.M., Davey G., Li M., Lew A.M., Blanas E., et al. CD8 T cell ignorance or tolerance to islet antigens depends on antigen dose. Proc Natl Acad Sci USA 96 22 (1999) 12703-12707
17. Choi S., and Schwartz R.H. Molecular mechanisms for adaptive tolerance and other T cell anergy models. Semin Immunol 19 3 (2007) 140-152
18. Schwartz R.H. T cell anergy. Annu Rev Immunol 21 (2003) 305-334
19. Young D.A., Lowe L.D., Booth S.S., Whitters M.J., Nicholson L., Kuchroo V.K., et al. IL-4. IL-10, IL-13, and TGF-beta from an altered peptide ligand-specific Th2 cell clone down-regulate adoptive transfer of experimental autoimmune encephalomyelitis. J Immunol 164 7 (2000) 3563-3572
20. Rocken M., and Shevach E.M. Immune deviation-the third dimension of nondeletional T cell tolerance. Immunol Rev 149 (1996) 175-194
21. Tian J., Clare-Salzler M., Herschenfeld A., Middleton B., Newman D., Mueller R., et al. Modulating autoimmune responses to GAD inhibits disease progression and prolongs islet graft survival in diabetes-prone mice. Nat Med 2 12 (1996) 1348-1353
22. Sakaguchi S., Ono M., Setoguchi R., Yagi H., Hori S., Fehervari Z., et al. Foxp3+ CD25+ CD4+ natural regulatory T cells in dominant self-tolerance and autoimmune disease. Immunol Rev 212 (2006) 8-27
23. Shevach E.M., DiPaolo R.A., Andersson J., Zhao D.M., Stephens G.L., and Thornton A.M. The lifestyle of naturally occurring CD4+ CD25+ Foxp3+ regulatory T cells. Immunol Rev 212 (2006) 60-73
24. Mellor A.L., and Munn D.H. IDO expression by dendritic cells: tolerance and tryptophan catabolism. Nat Rev Immunol 4 10 (2004) 762-774
25. Fallarino F., Grohmann U., Hwang K.W., Orabona C., Vacca C., Bianchi R., et al. Modulation of tryptophan catabolism by regulatory T cells. Nat Immunol 4 12 (2003) 1206-1212
26. Levine S., Sowinski R., and Kies M.W. Treatment of experimental allergic encephalomyelitis with encephalitogenic basic proteins. Proc Soc Exp Biol Med 139 2 (1972) 506-510
27. Atkinson M.A., and Leiter E.H. The NOD mouse model of type 1 diabetes: as good as it gets?. Nat Med 5 6 (1999) 601-604
28. Boussiotis V.A., Freeman G.J., Gray G., Gribben J., and Nadler L.M. B7 but not intercellular adhesion molecule-1 costimulation prevents the induction of human alloantigen-specific tolerance. J Exp Med 178 5 (1993) 1753-1763
29. Thorstenson K.M., and Khoruts A. Generation of anergic and potentially immunoregulatory CD25+CD4 T cells in vivo after induction of peripheral tolerance with intravenous or oral antigen. J Immunol 167 1 (2001) 188-195
30. Norman P.S., Nicodemus C.F., Creticos P.S., Wood R.A., Eggleston P.A., Lichtenstein L.M., et al. Clinical and immunologic effects of component peptides in Allervax Cat. Int Arch Allergy Immunol 113 1-3 (1997) 224-226
31. Bousquet J., Lockey R., Malling H.J., Alvarez-Cuesta E., Canonica G.W., Chapman M.D., et al. Allergen immunotherapy: therapeutic vaccines for allergic diseases. World Health Organization. American academy of Allergy, Asthma and Immunology. Ann Allergy Asthma Immunol 81 5 Pt 1 (1998) 401-405
32. Warren K.G., Catz I., and Wucherpfennig K.W. Tolerance induction to myelin basic protein by intravenous synthetic peptides containing epitope P85 VVHFFKNIVTP96 in chronic progressive multiple sclerosis. J Neurol Sci 152 1 (1997) 31-38
33. Khoury S.J., Lider O., al-Sabbagh A., and Weiner H.L. Suppression of experimental autoimmune encephalomyelitis by oral administration of myelin basic protein. III. Synergistic effect of lipopolysaccharide. Cell Immunol 131 2 (1990) 302-310
34. Zhang Z.J., Davidson L., Eisenbarth G., and Weiner H.L. Suppression of diabetes in nonobese diabetic mice by oral administration of porcine insulin. Proc Natl Acad Sci USA 88 22 (1991) 10252-10256
35. Mowat A.M., Parker L.A., Beacock-Sharp H., Millington O.R., and Chirdo F. Oral tolerance: overview and historical perspectives. Ann NY Acad Sci 1029 (2004) 1-8
36. Meyer O. Oral immunomodulation therapy in rheumatoid arthritis. Joint Bone Spine 67 5 (2000) 384-392
37. Faria A.M., and Weiner H.L. Oral tolerance. Immunol Rev 206 (2005) 232-259
38. Ohnishi Y., Tsutsumi A., Sakamaki T., and Sumida T. T cell epitopes of type II collagen in HLA-DRB1*0101 or DRB1*0405-positive Japanese patients with rheumatoid arthritis. Int J Mol Med 11 3 (2003) 331-335
39. Zhu P., Li X.Y., Wang H.K., et al. Oral administration of type-II collagen peptide 250-270 suppresses specific cellular and humoral immune response in collagen-induced arthritis. Clin Immunol 122 1 (2007) 75-84
40. Min S.Y., Hwang S.Y., Park K.S., Lee J.S., Lee K.E., Kim K.W., et al. Induction of IL-10-producing CD4+CD25+ T cells in animal model of collagen-induced arthritis by oral administration of type II collagen. Arthritis Res Ther 6 3 (2004) R213-R219
41. Morgan M.E., Sutmuller R.P., Witteveen H.J., van Duivenvoorde L.M., Zanelli E., Melief C.J., et al. CD25+ cell depletion hastens the onset of severe disease in collagen-induced arthritis. Arthritis Rheum 48 5 (2003) 1452-1460
42. Taneja V., Taneja N., Paisansinsup T., Behrens M., Griffiths M., Luthra H., et al. CD4 and CD8 T cells in susceptibility/protection to collagen-induced arthritis in HLA-DQ8-transgenic mice: implications for rheumatoid arthritis. J Immunol 168 11 (2002) 5867-5875
43. Morgan M.E., Witteveen H.J., Sutmuller R.P., de Vries R.R., and Toes R.E. CD25+ regulatory cells from HLA-DQ8 transgenic mice are capable of modulating collagen-induced arthritis. Hum Immunol 65 11 (2004) 1319-1327
44. Blanas E., and Heath W.R. Oral administration of antigen can lead to the onset of autoimmune disease. Int Rev Immunol 18 3 (1999) 217-228
45. Sloan-Lancaster J., and Allen P.M. Altered peptide ligand-induced partial T cell activation: molecular mechanisms and role in T cell biology. Annu Rev Immunol 14 (1996) 1-27
46. Franco A., Southwood S., Arrhenius T., Kuchroo V.K., Grey H.M., Sette A., et al. T cell receptor antagonist peptides are highly effective inhibitors of experimental allergic encephalomyelitis. Eur J Immunol 24 4 (1994) 940-946
47. Steinman L., Utz P.J., and Robinson W.H. Suppression of autoimmunity via microbial mimics of altered peptide ligands. Curr Top Microbiol Immunol 296 (2005) 55-63
48. Platten M., Ho P.P., Youssef S., Fontoura P., Garren H., Hur E.M., et al. Treatment of autoimmune neuroinflammation with a synthetic tryptophan metabolite. Science 310 5749 (2005) 850-855
49. Liu E., Moriyama H., Abiru N., Paronen J., Devendra D., Finkelman F.D., et al. Preventing peptide-induced anaphylaxis: addition of C-terminal amino acids to produce a neutral isoelectric point. J Allergy Clin Immunol 114 3 (2004) 607-613
50. Pearson C.M. Development of arthritis, periarthritis and periostitis in rats given adjuvants. Proc Soc Exp Biol Med 91 1 (1956) 95-101
51. Billingham M. Adjuvant arthritis: the first model. Mech Models Rheum Arthritis (1995) 389-409
52. Satpute S.R., Soukhareva N., Scott D.W., and Moudgil K.D. Mycobacterial Hsp65-IgG-expressing tolerogenic B cells confer protection against adjuvant-induced arthritis in Lewis rats. Arthritis Rheum 56 5 (2007) 1490-1496
53. Cobelens P.M., Heijnen C.J., Nieuwenhuis E.E., Kramer P.P., van der Zee R., van Eden W., et al. Treatment of adjuvant-induced arthritis by oral administration of mycobacterial Hsp65 during disease. Arthritis Rheum 43 12 (2000) 2694-2702
54. Haque M.A., Yoshino S., Inada S., Nomaguchi H., Tokunaga O., and Kohashi O. Suppression of adjuvant arthritis in rats by induction of oral tolerance to mycobacterial 65-kDa heat shock protein. Eur J Immunol 26 11 (1996) 2650-2656
55. Satpute SR, Moudgil KD. Protection against autoimmune arthritis induced by hsp65-mediated tolerance involves enhanced production of both IFN-g and antigen-specific antibodies (abstract 128.23). In: Immunology 2007; 94th Annual Meeting of The American Association of Immunologists. Miami Beach, Florida; 2007.
56. Ally B.A., Hawley T.S., McKall-Faienza K.J., Kundig T.M., Oehen S.U., Pircher H., et al. Prevention of autoimmune disease by retroviral-mediated gene therapy. J Immunol 155 11 (1995) 5404-5408
57. Bagley J., and Iacomini J. Gene therapy progress and prospects: gene therapy in organ transplantation. Gene Ther 10 8 (2003) 605-611
58. Siatskas C., Chan J., Field J., Murphy K., Nasa Z., Toh B.H., et al. Gene therapy strategies towards immune tolerance to treat the autoimmune diseases. Curr Gene Ther 6 1 (2006) 45-58
59. Chernajovsky Y., Gould D.J., and Podhajcer O.L. Gene therapy for autoimmune diseases: quo vadis?. Nat Rev Immunol 4 10 (2004) 800-811
60. Zambidis E.T., and Scott D.W. Epitope-specific tolerance induction with an engineered immunoglobulin. Proc Natl Acad Sci USA 93 10 (1996) 5019-5024
61. Kang Y., Melo M., Deng E., Tisch R., El-Amine M., and Scott D.W. Induction of hyporesponsiveness to intact foreign protein via retroviral-mediated gene expression: the IgG scaffold is important for induction and maintenance of immune hyporesponsiveness. Proc Natl Acad Sci USA 96 15 (1999) 8609-8614
62. Agarwal R.K., Kang Y., Zambidis E., Scott D.W., Chan C.C., and Caspi R.R. Retroviral gene therapy with an immunoglobulin-antigen fusion construct protects from experimental autoimmune uveitis. J Clin Invest 106 2 (2000) 245-252
63. El-Amine M., Hinshaw J.A., and Scott D.W. In vivo induction of tolerance by an Ig peptide is not affected by the deletion of FcR or a mutated IgG Fc fragment. Int Immunol 14 7 (2002) 761-766
64. Melo M.E., Qian J., El-Amine M., Agarwal R.K., Soukhareva N., Kang Y., et al. Gene transfer of Ig-fusion proteins into B cells prevents and treats autoimmune diseases. J Immunol 168 9 (2002) 4788-4795
65. Song L., Wang J., Wang R., Yu M., Sun Y., Han G., et al. Retroviral delivery of GAD-IgG fusion construct induces tolerance and modulates diabetes: a role for CD4+ regulatory T cells and TGF-beta?. Gene Ther 11 20 (2004) 1487-1496
66. Lei T.C., and Scott D.W. Induction of tolerance to factor VIII inhibitors by gene therapy with immunodominant A2 and C2 domains presented by B cells as Ig fusion proteins. Blood 105 12 (2005) 4865-4870
67. Xu B., Haviernik P., Wolfraim L.A., Bunting K.D., and Scott D.W. Bone marrow transplantation combined with gene therapy to induce antigen-specific tolerance and ameliorate EAE. Mol Ther 13 1 (2006) 42-48
68. Tarner I.H., Neumann E., Gay S., Fathman C.G., and Muller-Ladner U. Developing the concept of adoptive cellular gene therapy of rheumatoid arthritis. Autoimmun Rev 5 2 (2006) 148-152
69. Tarner I.H., Nakajima A., Seroogy C.M., Ermann J., Levicnik A., Contag C.H., et al. Retroviral gene therapy of collagen-induced arthritis by local delivery of IL-4. Clin Immunol 105 3 (2002) 304-314
70. Mukherjee P., Wu B., Mayton L., Kim S.H., Robbins P.D., and Wooley P.H. TNF receptor gene therapy results in suppression of IgG2a anticollagen antibody in collagen induced arthritis. Ann Rheum Dis 62 8 (2003) 707-714
71. Ho P.P., Higgins J.P., Kidd B.A., Tomooka B., Digennaro C., Lee L.Y., et al. Tolerizing DNA vaccines for autoimmune arthritis. Autoimmunity 39 8 (2006) 675-682
72. Bluestone J.A., and Tang Q. Therapeutic vaccination using CD4+CD25+ antigen-specific regulatory T cells. Proc Natl Acad Sci USA 101 Suppl 2 (2004) 14622-14626
73. Leipe J., Skapenko A., Lipsky P.E., and Schulze-Koops H. Regulatory T cells in rheumatoid arthritis. Arthritis Res Ther 7 3 (2005) 93
74. Kamphuis S., Albani S., and Prakken B.J. Heat-shock protein 60 as a tool for novel therapeutic strategies that target the induction of regulatory T cells in human arthritis. Exp Opin Biol Ther 6 6 (2006) 579-589
75. Prakken B.J., Samodal R., Le T.D., Giannoni F., Yung G.P., Scavulli J., et al. Epitope-specific immunotherapy induces immune deviation of proinflammatory T cells in rheumatoid arthritis. Proc Natl Acad Sci USA 101 12 (2004) 4228-4233
76. Ehrenstein M.R., Evans J.G., Singh A., Moore S., Warnes G., Isenberg D.A., et al. Compromised function of regulatory T cells in rheumatoid arthritis and reversal by anti-TNFalpha therapy. J Exp Med 200 3 (2004) 277-285
77. Valencia X., Yarboro C., Illei G., and Lipsky P.E. Deficient CD4+CD25high T regulatory cell function in patients with active systemic lupus erythematosus. J Immunol 178 4 (2007) 2579-2588
78. Prakken B., Kuis W., van Eden W., and Albani S. Heat shock proteins in juvenile idiopathic arthritis: keys for understanding remitting arthritis and candidate antigens for immune therapy. Curr Rheumatol Rep 4 6 (2002) 466-473
79. Koffeman E.C., Prakken B., and Albani S. Recent developments in immunomodulatory peptides in juvenile rheumatic diseases: from trigger to dimmer?. Curr Opin Rheumatol 17 5 (2005) 600-605
80. Vally M., Seenu S., and Pillarisetti S. Emerging peptide therapeutics for inflammatory diseases. Curr Pharm Biotechnol 7 4 (2006) 241-246
81. Zaliauskiene L., Fazio R.L., Kang S., Sparks K., Weaver C.T., Zinn K.R., et al. Inhibition of T cell responses by transferrin-coupled competitor peptides. Immunol Res 26 1-3 (2002) 77-85
82. Bielekova B., Goodwin B., Richert N., Cortese I., Kondo T., Afshar G., et al. Encephalitogenic potential of the myelin basic protein peptide (amino acids 83-99) in multiple sclerosis: results of a phase II clinical trial with an altered peptide ligand. Nat Med 6 10 (2000) 1167-1175
83. Kappos L., Comi G., Panitch H., Oger J., Antel J., Conlon P., et al. Induction of a non-encephalitogenic type 2 T helper-cell autoimmune response in multiple sclerosis after administration of an altered peptide ligand in a placebo-controlled, randomized phase II trial. The Altered Peptide Ligand in Relapsing MS Study Group. Nat Med 6 10 (2000) 1176-1182
84. Cravens P.D., and Lipsky P.E. Dendritic cells, chemokine receptors and autoimmune inflammatory diseases. Immunol Cell Biol 80 5 (2002) 497-505
85. van Duivenvoorde L.M., van Mierlo G.J., Boonman Z.F., and Toes R.E. Dendritic cells: vehicles for tolerance induction and prevention of autoimmune diseases. Immunobiology 211 6-8 (2006) 627-632
86. van Duivenvoorde L.M., Louis-Plence P., Apparailly F., et al. Antigen-specific immunomodulation of collagen-induced arthritis with tumor necrosis factor-stimulated dendritic cells. Arthritis Rheum 50 10 (2004) 3354-6364
87. Trentham D.E., Dynesius-Trentham R.A., Orav E.J., Combitchi D., Lorenzo C., Sewell K.L., et al. Effects of oral administration of type II collagen on rheumatoid arthritis. Science 261 5129 (1993) 1727-1730
88. McKown K.M., Carbone L.D., Kaplan S.B., Aelion J.A., Lohr K.M., Cremer M.A., et al. Lack of efficacy of oral bovine type II collagen added to existing therapy in rheumatoid arthritis. Arthritis Rheum 42 6 (1999) 1204-1208
89. Nussenblatt R.B., Gery I., Weiner H.L., Ferris F.L., Shiloach J., Remaley N., et al. Treatment of uveitis by oral administration of retinal antigens: results of a phase I/II randomized masked trial. Am J Ophthalmol 123 5 (1997) 583-592
90. Chaillous L., Lefevre H., Thivolet C., Boitard C., Lahlou N., Atlan-Gepner C., et al. Oral insulin administration and residual beta-cell function in recent-onset type 1 diabetes: a multicentre randomised controlled trial. Diabete Insuline Orale group. Lancet 356 9229 (2000) 545-549
91. Staines N.A., Derry C.J., Marinova-Mutafchieva L., Ali N., Davies D.H., and Murphy J.J. Constraints on the efficacy of mucosal tolerance in treatment of human and animal arthritic diseases. Ann NY Acad Sci 1029 (2004) 250-259
92. Postlethwaite A.E. Can we induce tolerance in rheumatoid arthritis?. Curr Rheumatol Rep 3 1 (2001) 64-69
93. Trentham D.E. Oral tolerization as a treatment of rheumatoid arthritis. Rheum Dis Clin North Am 24 3 (1998) 525-536
94. Buckner J.H., and Nepom G.T. Genetics of rheumatoid arthritis: is there a scientific explanation for the human leukocyte antigen association?. Curr Opin Rheumatol 14 3 (2002) 254-259
95. David C.S., and Taneja V. Role of major histocompatibility complex genes in murine collagen-induced arthritis: a model for human rheumatoid arthritis. Am J Med Sci 327 4 (2004) 180-187
96. Deighton C., and Criswell L.A. Recent advances in the genetics of rheumatoid arthritis. Curr Rheumatol Rep 8 5 (2006) 394-400
97. Klareskog L., Padyukov L., Ronnelid J., and Alfredsson L. Genes, environment and immunity in the development of rheumatoid arthritis. Curr Opin Immunol 18 6 (2006) 650-655
98. van der Helm-van Mil A.H., Verpoort K.N., Breedveld F.C., Huizinga T.W., Toes R.E., and de Vries R.R. The HLA-DRB1 shared epitope alleles are primarily a risk factor for anti-cyclic citrullinated peptide antibodies and are not an independent risk factor for development of rheumatoid arthritis. Arthritis Rheum 54 4 (2006) 1117-1121
99. Moudgil K.D., Chang T.T., Eradat H., et al. Diversification of T cell responses to carboxy-terminal determinants within the 65-kD heat-shock protein is involved in regulation of autoimmune arthritis. J Exp Med 185 7 (1997) 1307-1316
100. Stevens D.B., Gold D.P., Sercarz E.E., and Moudgil K.D. The Wistar Kyoto (RT1(l)) rat is resistant to myelin basic protein-induced experimental autoimmune encephalomyelitis: comparison with the susceptible Lewis (RT1(l)) strain with regard to the MBP-directed CD4+ T cell repertoire and its regulation. J Neuroimmunol 126 1-2 (2002) 25-36
101. Chatenoud L., Salomon B., and Bluestone J.A. Suppressor T cells-they're back and critical for regulation of autoimmunity!. Immunol Rev 182 (2001) 149-163
102. Read S., Malmstrom V., and Powrie F. Cytotoxic T lymphocyte-associated antigen 4 plays an essential role in the function of CD25(+)CD4(+) regulatory cells that control intestinal inflammation. J Exp Med 192 2 (2000) 295-302
103. Edinger M., Hoffmann P., Ermann J., Drago K., Fathman C.G., Strober S., et al. CD4+CD25+ regulatory T cells preserve graft-versus-tumor activity while inhibiting graft-versus-host disease after bone marrow transplantation. Nat Med 9 9 (2003) 1144-1150
104. Wu A.J., Hua H., Munson S.H., and McDevitt H.O. Tumor necrosis factor-alpha regulation of CD4+CD25+ T cell levels in NOD mice. Proc Natl Acad Sci USA 99 19 (2002) 12287-12292
105. Viglietta V., Baecher-Allan C., Weiner H.L., and Hafler D.A. Loss of functional suppression by CD4+CD25+ regulatory T cells in patients with multiple sclerosis. J Exp Med 199 7 (2004) 971-979
106. Kang H.K., Michaels M.A., Berner B.R., and Datta S.K. Very low-dose tolerance with nucleosomal peptides controls lupus and induces potent regulatory T cell subsets. J Immunol 174 6 (2005) 3247-3255
107. Yao Z., Fanslow W.C., Seldin M.F., Rousseau A.M., Painter S.L., Comeau M.R., et al. Herpesvirus Saimiri encodes a new cytokine. IL-17, which binds to a novel cytokine receptor Immunity 3 6 (1995) 811-821
108. Broxmeyer H.E. Is interleukin 17, an inducible cytokine that stimulates production of other cytokines, merely a redundant player in a sea of other biomolecules?. J Exp Med 183 6 (1996) 2411-2415
109. Bettelli E., Carrier Y., Gao W., Korn T., Strom T.B., Oukka M., et al. Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells. Nature 441 7090 (2006) 235-238
110. Veldhoen M., Hocking R.J., Atkins C.J., Locksley R.M., and Stockinger B. TGFbeta in the context of an inflammatory cytokine milieu supports de novo differentiation of IL-17-producing T cells. Immunity 24 2 (2006) 179-189
111. Bettelli E., Oukka M., and Kuchroo V.K. T(H)-17 cells in the circle of immunity and autoimmunity. Nat Immunol 8 4 (2007) 345-350
112. Langrish C.L., Chen Y., Blumenschein W.M., Mattson J., Basham B., Sedgwick J.D., et al. IL-23 drives a pathogenic T cell population that induces autoimmune inflammation. J Exp Med 201 2 (2005) 233-240
113. Park H., Li Z., Yang X.O., Chang S.H., Nurieva R., Wang Y.H., et al. A distinct lineage of CD4 T cells regulates tissue inflammation by producing interleukin 17. Nat Immunol 6 11 (2005) 1133-1141
114. Laurence A., Tato C.M., Davidson T.S., Kanno Y., Chen Z., Yao Z., et al. Interleukin-2 signaling via STAT5 constrains T helper 17 cell generation. Immunity 26 3 (2007) 371-381
115. Amadi-Obi A., Yu C.R., Liu X., Mahdi R.M., Clarke G.L., Nussenblatt R.B., et al. T(H)17 cells contribute to uveitis and scleritis and are expanded by IL-2 and inhibited by IL-27/STAT1. Nat Med 13 6 (2007) 711-718
116. Ivanov I.I., McKenzie B.S., Zhou L., Tadokoro C.E., Lepelley A., Lafaille J.J., et al. The orphan nuclear receptor RORgammat directs the differentiation program of proinflammatory IL-17+ T helper cells. Cell 126 6 (2006) 1121-1133
117. Cua D.J., Sherlock J., Chen Y., Murphy C.A., Joyce B., Seymour B., et al. Interleukin-23 rather than interleukin-12 is the critical cytokine for autoimmune inflammation of the brain. Nature 421 6924 (2003) 744-748
118. Hofstetter H.H., Ibrahim S.M., Koczan D., Kruse N., Weishaupt A., Toyka K.V., et al. Therapeutic efficacy of IL-17 neutralization in murine experimental autoimmune encephalomyelitis. Cell Immunol 237 2 (2005) 123-130
119. Lubberts E., Joosten L.A., Oppers B., van den Bersselaar L., Coenen-de Roo C.J., Kolls J.K., et al. IL-1-independent role of IL-17 in synovial inflammation and joint destruction during collagen-induced arthritis. J Immunol 167 2 (2001) 1004-1013
120. Nakae S., Saijo S., Horai R., Sudo K., Mori S., and Iwakura Y. IL-17 production from activated T cells is required for the spontaneous development of destructive arthritis in mice deficient in IL-1 receptor antagonist. Proc Natl Acad Sci USA 100 10 (2003) 5986-5990
121. Vukkadapu S.S., Belli J.M., Ishii K., Jegga A.G., Hutton J.J., Aronow B.J., et al. Dynamic interaction between T cell-mediated beta-cell damage and beta-cell repair in the run up to autoimmune diabetes of the NOD mouse. Physiol Genom 21 2 (2005) 201-211
122. Mensah-Brown E.P., Shahin A., Al-Shamisi M., Wei X., and Lukic M.L. IL-23 leads to diabetes induction after subdiabetogenic treatment with multiple low doses of streptozotocin. Eur J Immunol 36 1 (2006) 216-223
123. Chabaud M., Fossiez F., Taupin J.L., and Miossec P. Enhancing effect of IL-17 on IL-1-induced IL-6 and leukemia inhibitory factor production by rheumatoid arthritis synoviocytes and its regulation by Th2 cytokines. J Immunol 161 1 (1998) 409-414
124. Weiner L.P., Louie K.A., Atalla L.R., Kochounian H.H., Du J., Wei W., et al. Gene therapy in a murine model for clinical application to multiple sclerosis. Ann Neurol 55 3 (2004) 390-399
125. Lei T.C., Su Y., and Scott D.W. Tolerance induction via a B-cell delivered gene therapy-based protocol: optimization and role of the Ig scaffold. Cell Immunol 235 1 (2005) 12-20
126. Litzinger M.T., Su Y., Lei T.C., Soukhareva N., and Scott D.W. Mechanisms of gene therapy for tolerance: B7 signaling is required for peptide-IgG gene-transferred tolerance induction. J Immunol 175 2 (2005) 780-787
127. Soukhareva N., Jiang Y., and Scott D.W. Treatment of diabetes in NOD mice by gene transfer of Ig-fusion proteins into B cells: role of T regulatory cells. Cell Immunol 240 1 (2006) 41-46
128. Huang H., Kearney J.F., Grusby M.J., Benoist C., and Mathis D. Induction of tolerance in arthritogenic B cells with receptors of differing affinity for self-antigen. Proc Natl Acad Sci USA 103 10 (2006) 3734-3739
129. van Gaalen F.A., Toes R.E., Ditzel H.J., Schaller M., Breedveld F.C., Verweij C.L., et al. Association of autoantibodies to glucose-6-phosphate isomerase with extraarticular complications in rheumatoid arthritis. Arthritis Rheum 50 2 (2004) 395-399
130. Morris-Downes M.M., Smith P.A., Rundle J.L., Piddlesden S.J., Baker D., Pham-Dinh D., et al. Pathological and regulatory effects of anti-myelin antibodies in experimental allergic encephalomyelitis in mice. J Neuroimmunol 125 1-2 (2002) 114-124
131. Ulmansky R., and Naparstek Y. Immunoglobulins from rats that are resistant to adjuvant arthritis suppress the disease in arthritis-susceptible rats. Eur J Immunol 25 4 (1995) 952-957
132. Kabelitz D. Expression and function of Toll-like receptors in T lymphocytes. Curr Opin Immunol 19 1 (2007) 39-45
133. Pasare C., and Medzhitov R. Toll-dependent control mechanisms of CD4 T cell activation. Immunity 21 5 (2004) 733-741
134. Marshak-Rothstein A., and Rifkin I.R. Immunologically active autoantigens: the role of toll-like receptors in the development of chronic inflammatory disease. Annu Rev Immunol 25 (2007) 419-441
135. Lanzavecchia A., and Sallusto F. Toll-like receptors and innate immunity in B-cell activation and antibody responses. Curr Opin Immunol 19 3 (2007) 268-274
136. Medvedev A.E., Sabroe I., Hasday J.D., and Vogel S.N. Tolerance to microbial TLR ligands: molecular mechanisms and relevance to disease. J Endotoxin Res 12 3 (2006) 133-150
137. Metz M., and Maurer M. Mast cells-key effector cells in immune responses. Trends Immunol 28 5 (2007) 234-241
138. Lee D.M., Friend D.S., Gurish M.F., Benoist C., Mathis D., and Brenner M.B. Mast cells: a cellular link between autoantibodies and inflammatory arthritis. Science 297 5587 (2002) 1689-1692
139. Flierman R., and Daha M.R. The clearance of apoptotic cells by complement. Immunobiology 212 4-5 (2007) 363-370
140. Monach P.A., Verschoor A., Jacobs J.P., Carroll M.C., Wagers A.J., Benoist C., et al. Circulating C3 is necessary and sufficient for induction of autoantibody-mediated arthritis in a mouse model. Arthritis Rheum 56 9 (2007) 2968-2974
141. Huang Q., Ma Y., Adebayo A., and Pope R.M. Increased macrophage activation mediated through toll-like receptors in rheumatoid arthritis. Arthritis Rheum 56 7 (2007) 2192-2201
142. Radstake T.R., Roelofs M.F., Jenniskens Y.M., Oppers-Walgreen B., van Riel P.L., Barrera P., et al. Expression of toll-like receptors 2 and 4 in rheumatoid synovial tissue and regulation by proinflammatory cytokines interleukin-12 and interleukin-18 via interferon-gamma. Arthritis Rheum 50 12 (2004) 3856-3865
143. Sacre S.M., Andreakos E., Kiriakidis S., Amjadi P., Lundberg A., Giddins G., et al. The Toll-like receptor adaptor proteins MyD88 and Mal/TIRAP contribute to the inflammatory and destructive processes in a human model of rheumatoid arthritis. Am J Pathol 170 2 (2007) 518-525
144. Christensen S.R., Shupe J., Nickerson K., Kashgarian M., Flavell R.A., and Shlomchik M.J. Toll-like receptor 7 and TLR9 dictate autoantibody specificity and have opposing inflammatory and regulatory roles in a murine model of lupus. Immunity 25 3 (2006) 417-428
145. You X., Pan M., Gao W., Shiah H.S., Tao J., Zhang D., et al. Effects of a novel tylophorine analog on collagen-induced arthritis through inhibition of the innate immune response. Arthritis Rheum 54 3 (2006) 877-886
146. Banda N.K., Kraus D., Vondracek A., Huynh L.H., Bendele A., Holers V.M., et al. Mechanisms of effects of complement inhibition in murine collagen-induced arthritis. Arthritis Rheum 46 11 (2002) 3065-3075
147. Abdollahi-Roodsaz S., Joosten L.A., Roelofs M.F., Radstake T.R., Matera G., Popa C., et al. Inhibition of toll-like receptor 4 breaks the inflammatory loop in autoimmune destructive arthritis. Arthritis Rheum 56 9 (2007) 2957-2967
148. De Jager P.L., and Hafler D.A. New therapeutic approaches for multiple sclerosis. Annu Rev Med 58 (2007) 417-432
149. Gumanovskaya M.L., Myers L.K., Rosloniec E.F., Stuart J.M., and Kang A.H. Intravenous tolerization with type II collagen induces interleukin-4-and interleukin-10-producing CD4+ T cells. Immunology 97 3 (1999) 466-473
150. Yang X.D., Gasser J., Riniker B., and Feige U. Treatment of adjuvant arthritis in rats: vaccination potential of a synthetic nonapeptide from the 65 kDa heat shock protein of mycobacteria. J Autoimmun 3 1 (1990) 11-23
151. Turley D.M., and Miller S.D. Peripheral tolerance induction using ethylenecarbodiimide-fixed APCs uses both direct and indirect mechanisms of antigen presentation for prevention of experimental autoimmune encephalomyelitis. J Immunol 178 4 (2007) 2212-2220
152. Sriram S., Schwartz G., and Steinman L. Administration of myelin basic protein-coupled spleen cells prevents experimental allergic encephalitis. Cell Immunol 75 2 (1983) 378-382
153. Durai M., Kim H.R., and Moudgil K.D. The regulatory C-terminal determinants within mycobacterial heat shock protein 65 are cryptic and cross-reactive with the dominant self homologs: implications for the pathogenesis of autoimmune arthritis. J Immunol 173 1 (2004) 181-188
154. Golden H.W., Maniglia C.A., and Ranges G.E. A synthetic mycobacterial heat shock peptide prevents adjuvant arthritis but not proteoglycan-induced synovitis in the rat. Agents Actions 34 1-2 (1991) 148-150
155. Mia M.Y., Durai M., Kim H.R., and Moudgil K.D. Heat shock protein 65-reactive T cells are involved in the pathogenesis of non-antigenic dimethyl dioctadecyl ammonium bromide-induced arthritis. J Immunol 175 1 (2005) 219-227
156. Ditzian-Kadanoff R. Testicular-associated immune deviation and prevention of adjuvant-induced arthritis by three tolerization methods. Scand J Immunol 50 2 (1999) 150-158
157. van Eden W., Thole J.E., van der Zee R., Noordzij A., van Embden J.D., Hensen E.J., et al. Cloning of the mycobacterial epitope recognized by T lymphocytes in adjuvant arthritis. Nature 331 6152 (1988) 171-173
158. Kingston A.E., Hicks C.A., Colston M.J., and Billingham M.E. A 71-kD heat shock protein (hsp) from Mycobacterium tuberculosis has modulatory effects on experimental rat arthritis. Clin Exp Immunol 103 1 (1996) 77-82
159. Agnello D., Scanziani E., Di G.M., Leoni F., Modena D., Mascagni P., et al. Preventive administration of Mycobacterium tuberculosis 10-kDa heat shock protein (hsp10) suppresses adjuvant arthritis in Lewis rats. Int Immunopharmacol 2 4 (2002) 463-474
160. Ding C.H., Li Q., Xiong Z.Y., Zhou A.W., Jones G., and Xu S.Y. Oral administration of type II collagen suppresses pro-inflammatory mediator production by synoviocytes in rats with adjuvant arthritis. Clin Exp Immunol 132 3 (2003) 416-423
161. Beech J.T., Siew L.K., Ghoraishian M., Stasiuk L.M., Elson C.J., and Thompson S.J. CD4+ Th2 cells specific for mycobacterial 65-kilodalton heat shock protein protect against pristane-induced arthritis. J Immunol 159 8 (1997) 3692-3697
162. Jorgensen C., Gedon E., Jaquet C., and Sany J. Gastric administration of recombinant 65 kDa heat shock protein delays the severity of type II collagen induced arthritis in mice. J Rheumatol 25 4 (1998) 763-767
163. van den Broek M.F., Hogervorst E.J., Van Bruggen M.C., Van Eden W., van der Zee R., and van den Berg W.B. Protection against streptococcal cell wall-induced arthritis by pretreatment with the 65-kD mycobacterial heat shock protein. J Exp Med 170 2 (1989) 449-466
164. Quintana F.J., Carmi P., Mor F., and Cohen I.R. DNA fragments of the human 60-kDa heat shock protein (HSP60) vaccinate against adjuvant arthritis: identification of a regulatory HSP60 peptide. J Immunol 171 7 (2003) 3533-3541
165. Durai M., Gupta R.S., and Moudgil K.D. The T cells specific for the carboxyl-terminal determinants of self (rat) heat-shock protein 65 escape tolerance induction and are involved in regulation of autoimmune arthritis. J Immunol 172 5 (2004) 2795-2802
166. Anderton S.M., van der Zee R., Noordzij A., and van Eden W. Differential mycobacterial 65-kDa heat shock protein T cell epitope recognition after adjuvant arthritis-inducing or protective immunization protocols. J Immunol 152 7 (1994) 3656-3664
167. Prakken B.J., van der Zee R., Anderton S.M., van Kooten P.J., Kuis W., and van Eden W. Peptide-induced nasal tolerance for a mycobacterial heat shock protein 60 T cell epitope in rats suppresses both adjuvant arthritis and nonmicrobially induced experimental arthritis. Proc Natl Acad Sci USA 94 7 (1997) 3284-3289
168. Francis J.N., Lamont A.G., and Thompson S.J. The route of administration of an immunodominant peptide derived from heat-shock protein 65 dramatically affects disease outcome in pristane-induced arthritis. Immunology 99 3 (2000) 338-344
169. Thompson S.J., Francis J.N., Siew L.K., Webb G.R., Jenner P.J., Colston M.J., et al. An immunodominant epitope from mycobacterial 65-kDa heat shock protein protects against pristane-induced arthritis. J Immunol 160 9 (1998) 4628-4634
170. Wauben M.H., Boog C.J., van der Zee R., Joosten I., Schlief A., and van Eden W. Disease inhibition by major histocompatibility complex binding peptide analogues of disease-associated epitopes: more than blocking alone. J Exp Med 176 3 (1992) 667-677
171. Prakken B.J., Roord S., van Kooten P.J., Wagenaar J.P., van Eden W., Albani S., et al. Inhibition of adjuvant-induced arthritis by interleukin-10-driven regulatory cells induced via nasal administration of a peptide analog of an arthritis-related heat-shock protein 60 T cell epitope. Arthritis Rheum 46 7 (2002) 1937-1946
172. Sakurai Y., Brand D.D., Tang B., Rosloniec E.F., Stuart J.M., Kang A.H., et al. Analog peptides of type II collagen can suppress arthritis in HLA-DR4 (DRB1*0401) transgenic mice. Arthritis Res Ther 8 5 (2006) R150
173. Buzas E.I., Hanyecz A., Murad Y., Hudecz F., Rajnavolgyi E., Mikecz K., et al. Differential recognition of altered peptide ligands distinguishes two functionally discordant (arthritogenic and nonarthritogenic) autoreactive T cell hybridoma clones. J Immunol 171 6 (2003) 3025-3033
174. Quintana F.J., Carmi P., Mor F., and Cohen I.R. Inhibition of adjuvant arthritis by a DNA vaccine encoding human heat shock protein 60. J Immunol 169 6 (2002) 3422-3428
175. Hogervorst E.J., Schouls L., Wagenaar J.P., Boog C.J., Spaan W.J., van Embden J.D., et al. Modulation of experimental autoimmunity: treatment of adjuvant arthritis by immunization with a recombinant vaccinia virus. Infect Immun 59 6 (1991) 2029-2035
176. Lopez-Guerrero J.A., Ortiz M.A., Paez E., Bernabeu C., and Lopez-Bote J.P. Therapeutic effect of recombinant vaccinia virus expressing the 60-kd heat-shock protein on adjuvant arthritis. Arthritis Rheum 37 10 (1994) 1462-1467
177. Esaguy N., and Aguas A.P. Prevention of adjuvant arthritis in Lewis rats by neonatal bacille Calmette-Guerin (BCG) infection. Clin Exp Immunol 104 1 (1996) 103-107
178. Thompson S.J., Butcher P.D., Patel V.K., Rook G.A., Stanford J., van der Zee R., et al. Modulation of pristane-induced arthritis by mycobacterial antigens. Autoimmunity 11 1 (1991) 35-43